Prosecution Insights
Last updated: April 19, 2026

Examiner: BORI, IBRAHIM D

Tech Center 1600 • Art Units: 1629

This examiner grants 43% of resolved cases

Performance Statistics

43.2%
Allow Rate
-16.8% vs TC avg
634
Total Applications
+38.0%
Interview Lift
1226
Avg Prosecution Days
Based on 590 resolved cases, 2023–2026

Rejection Statute Breakdown

2.4%
§101 Eligibility
17.1%
§102 Novelty
36.6%
§103 Obviousness
25.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18442086 ANTICONVULSANT ACTIVITY OF STEROIDS Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18261590 POWDEROUS COMPOSITION(II) Non-Final OA DSM IP ASSETS B.V.
17248254 REDUCED INHALATION HAZARD OF QUATERNARY AMMONIUM COMPOUNDS-PH DRIVEN PHYSIOLOGICAL RESPONSE Non-Final OA ECOLAB USA INC.
17793963 THICKENER Final Rejection KANEKA CORPORATION
18045793 Polytherapy Modulating Cathelicidin Gene Expression Modulation for The Treatment of Alzheimer's Disease and Other Conditions Final Rejection The Board of Trustees of the Leland Stanford Junior University
18579135 METHODS FOR HAIR GROWTH Non-Final OA THE REGENTS OF THE UNIVERSITY OF MICHIGAN
18037943 HAIR GROWTH STIMULANT Non-Final OA RIKEN
17044684 DIETARY BUTYRATE Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
17736305 Formulations/Compositions Comprising a BTK Inhibitor Final Rejection Janssen Pharmaceutica NV
16967911 FRAGRANCE COMPOSITIONS AND USES THEREOF Non-Final OA Coty Inc.
16975043 PARENTERAL FORMULATION MATERIALS AND METHODS FOR 40-O-CYCLIC HYDROCARBON ESTERS AND RELATED STRUCTURES Final Rejection Biotronik AG
18777376 METHODS OF ORAL CONTRACEPTION BY CONTROLLED RELEASE OF DIENOGEST AND ETHYNYL ESTRADIOL Final Rejection CHEMO RESEARCH, S.L.
18750843 HIGH POTENCY EMULSIONS Non-Final OA Vertosa Inc.
18745512 MODIFIED CHOLIC ACID CONJUGATES Final Rejection Ultra, LLC
18418121 METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE Non-Final OA ZOGENIX INTERNATIONAL LIMITED
18418133 METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE Non-Final OA ZOGENIX INTERNATIONAL LIMITED
17107099 COMBINATION THERAPY OF LYMPHOMA Final Rejection Universität Heidelberg
18268726 OIL BALM CLEANSING COSMETIC COMPOSITION Non-Final OA L V M H RECHERCHE
18398952 Rapid Onset Therapeutic Anti-Depression Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Methods and Compounds for Psilocybin co-administration Non-Final OA American Ketone Therapeutics LLC
18390537 Methods of Administering Myosin Inhibitors Final Rejection MYOKARDIA, INC.
18571418 PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF Non-Final OA Abbisko Therapeutics Co., Ltd.
18541391 ANTICOAGULANT REVERSAL AGENTS Non-Final OA COVIS Pharma GmbH
17682822 ANTIVIRAL EFFECTS OF NARASIN IN SWINE FEED Final Rejection Elanco US Inc.
18499940 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY Final Rejection ASTEX THERAPEUTICS LIMITED
18460648 METHODS OF TREATING HYPERSENSITIVE COUGH OR ITCHING USING ION CHANNEL INHIBITORY COMPOUNDS Final Rejection AFASCI, Inc.
18447040 THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF Non-Final OA Tvardi Operating Company, Inc.
15939329 ADMINISTRATION OF TAILORED FEEDSTOCK TO INCREASE ANTIBIOTIC SUSCEPTIBILITY Non-Final OA U.S. Army Research Laboratory

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month